Sanofi SA (EPA:SAN) has earned a consensus recommendation of “Hold” from the fifteen brokerages that are covering the firm. One analyst has rated the stock with a sell rating, eight have given a hold rating and six have given a buy rating to the company. The average 12-month price target among brokers that have issued a report on the stock in the last year is €83.57 ($89.86).

Several brokerages have recently commented on SAN. Jefferies Group set a €78.00 ($83.87) price target on shares of Sanofi SA and gave the stock a “neutral” rating in a research report on Friday, November 11th. Goldman Sachs Group Inc. set a €83.00 ($89.25) price target on shares of Sanofi SA and gave the stock a “neutral” rating in a research report on Monday, November 7th. Morgan Stanley set a €77.00 ($82.80) price target on shares of Sanofi SA and gave the stock a “neutral” rating in a research report on Friday, November 4th. Berenberg Bank set a €92.00 ($98.92) price target on shares of Sanofi SA and gave the stock a “buy” rating in a research report on Tuesday, November 1st. Finally, Sanford C. Bernstein set a €77.00 ($82.80) price objective on shares of Sanofi SA and gave the stock a “neutral” rating in a research note on Monday, October 31st.

Sanofi SA (EPA:SAN) opened at 76.05 on Friday. The firm has a market cap of €97.88 billion and a price-to-earnings ratio of 23.34. The stock’s 50 day moving average is €25.60 and its 200 day moving average is €25.75. Sanofi SA has a 52 week low of €62.50 and a 52 week high of €84.81.

About Sanofi SA

Sanofi, formerly Sanofi-Aventis, is a healthcare company engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company operates through three segments: Pharmaceuticals, Human Vaccines (Vaccines) and Animal Health. The Pharmaceuticals segment consists of research, development, production and marketing of medicines, including those originating from Genzyme Corporation.

Receive News & Stock Ratings for Sanofi SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi SA and related stocks with our FREE daily email newsletter.